This review will inform the revision of WHO HIV treatment guidelines and guidance provided through WHO and UNAIDS Treatment 2.0 initiative. This initiaitive aims to catalyse the next phase of HIV treatment scale up through promoting innovation and efficiency gains, such as the development of more simplified, less toxic and more efficient antiretroviral (ARV) drug regimens.(1) This approach includes establishing optimal dosages of ARVs (including possible dose reductions of existing ARVs), reducing pill burden, using fixed-dose combinations (FDCs), improving paediatric formulations, and expanding access to effective, safer, and affordable first-, second- and third-line drug regimens.
|